Abstract:Estrogen receptor (ER)-positive breast cancer (BC) is the most common BC subtype. Endocrine therapy (ET) targeting ER signaling still remains the mainstay treatment option for hormone receptor (HR)-positive BC either in the early or in advanced setting, including different strategies, such as the suppression of estrogen production or directly blocking the ER pathway through SERMs—selective estrogen receptor modulators—or SERDs—selective estrogen receptor degraders. Nevertheless, the development of de novo or acquired endocrine resistance still remains challenging for oncologists. The use of novel ET combined with targeted drugs, such as cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, has significantly improved long-term outcome rates, thus changing the therapeutic algorithm for metastatic BC (MBC) and recently the therapeutic strategy in the adjuvant setting for early high-risk BC. Eluding the resistance to CDK4/6 inhibitors combined with ET is currently an unmet medical need, and there is disagreement concerning the best course of action for patients who continue to progress after this combination approach. Genetic changes in the tumor along its growth uncovered by genomic profiling of recurrent and/or metastatic lesions through tumor and/or liquid biopsies may predict the response or resistance to specific agents, suggesting the best therapeutic strategy for each patient by targeting the altered ER-dependent pathway (novel oral SERDs and a new generation of anti-estrogen agents) or alternative ER-independent signaling pathways such as PI3K/AKT/mTOR or tyrosine kinase receptors (HER2 mutations or HER2 low status) or by inhibiting pathways weakened through germline BRCA1/2 mutations. These agents are being investigated as single molecules and in combination with other target therapies, offering promising weapons to overcome or avoid treatment failure and propose increasingly more personalized treatment approaches. This review presents novel insights into ET and other targeted therapies for managing metastatic HR+/HER2− BC by exploring potential strategies based on clinical evidence and genomic profiling following the failure of the CDK4/6i and ET combination.

The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors

Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer

Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer

Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer

Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

Emerging Targeted Therapies for HER2-Positive Breast Cancer

Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer

The evolving landscape of metastatic HER2-positive, hormone receptor-positive breast cancer

Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies

New treatment options for hormone receptor positive breast cancer in 2023

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer

Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer

Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy

Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast Cancer

Treatment of HER2-positive breast cancer: current status and future perspectives

Novel Treatment Strategies for Patients with HER2-positive Breast Cancer Who Do Not Benefit from Current Targeted Therapy Drugs.

Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer